Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Rapidly Generated Multipathogen-specific T-Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections Post Allogeneic Stem Cell Transplant

NCT05471661 is registered in ClinicalTrials.gov with George Papanicolaou Hospital as lead sponsor.

NCT NCT05471661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05471661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Rapidly Generated Multipathogen-specific T-Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections Post Allogeneic Stem Cell Transplant
Lead sponsor
George Papanicolaou Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
May 22, 2021
Completion date
May 8, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow transplant infection, opportunistic fungal infection, opportunistic viral infection